Robert W. Gorter
Research Subjects
Robert W. Gorter has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Eloy Pulido Cobian
2 shared publicationsMario Butorac
2 shared publicationsMatthias Stoss
1 shared publicationPeter Joller
1 shared publication
Latest Publications
- 1 January 2005
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 12 (1) , 17-21
Cutaneous Resorption of Lead After External Use of Lead-Containing Ointments in Volunteers with Healthy Skin
Lead-containing ointments are frequently used in anthroposophic medicine. In a prospective, open-label phase 1 study, 33 volunteers at the Ambulatory Clinic for Complementary and Alternative Medicine at the Free University of Berlin, aged 18-65 years, were exposed to 100 g Plumbum metallicum 0.4% ointment (Weleda, Germany) over a 4-week period. The lead-containing ointment was regularly applied to the cubital side of the forearm. Regular measurements of lead concentrations in whole blood, urine, and scalp hair were determined. None of the 33 volunteers showed an increase in lead concentrations in the 3 investigated compartments after 4 and 8 weeks. Blood lead levels (average value) decreased significantly from baseline to the first week (P < 0.05). Average values in the following investigations (weeks 3, 4, and 8) were significantly lower than at baseline (P < 0.05). There was no increase in lead levels in the scalp hair after 8 weeks (P < 0.05). The results show that the commonly prescribed lead-containing ointment Plumbum metallicum 0.4% in humans with an intact skin does not present a toxic risk.
- 1 January 2005
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 12 (1) , 17-21
Cutaneous Resorption of Lead After External Use of Lead-Containing Ointments in Volunteers with Healthy Skin
Lead-containing ointments are frequently used in anthroposophic medicine. In a prospective, open-label phase 1 study, 33 volunteers at the Ambulatory Clinic for Complementary and Alternative Medicine at the Free University of Berlin, aged 18-65 years, were exposed to 100 g Plumbum metallicum 0.4% ointment (Weleda, Germany) over a 4-week period. The lead-containing ointment was regularly applied to the cubital side of the forearm. Regular measurements of lead concentrations in whole blood, urine, and scalp hair were determined. None of the 33 volunteers showed an increase in lead concentrations in the 3 investigated compartments after 4 and 8 weeks. Blood lead levels (average value) decreased significantly from baseline to the first week (P < 0.05). Average values in the following investigations (weeks 3, 4, and 8) were significantly lower than at baseline (P < 0.05). There was no increase in lead levels in the scalp hair after 8 weeks (P < 0.05). The results show that the commonly prescribed lead-containing ointment Plumbum metallicum 0.4% in humans with an intact skin does not present a toxic risk.
- 1 November 2004
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 11 (6) , 453-458
Examination of the Cutaneous Absorption of Copper After the Use of Copper-Containing Ointments
Because copper-containing ointments are frequently used in anthroposophical medicine, a phase I trial to investigate the cutaneous absorption of copper was conducted. Sixty-one volunteers were randomized [group A: 0.4% copper (I) oxide, 13 men and 18 women (19–55 years); group B: 20% elementary copper, 11 men and 19 women (18–70 years)]. The ointment was applied over a 4-week period followed by a 4-week wash-out phase. Serum and urine copper concentrations were measured by atomic absorption spectrometry and hair copper concentration by inductive coupled plasma mass spectrometry. For statistical analysis, the Student t test for related random samples was used; α = 0.05 was chosen for the standard error. In group A, an increase of copper in serum and scalp hair and a decrease in urine were found in the study period. The mean serum concentration in all premenopausal women using oral contraceptives was above normal. In group B, the serum copper concentration increased significantly; in urine, it decreased, and in scalp hair, it remained stable. A higher level of serum copper was found in female volunteers using hormonal contraception. Treatment with the 2 different ointments did not cause toxic irritations on the skin, and it can therefore be deduced that the appropriate application of ointment preparations containing copper in concentrations up to 20% do not present a toxic risk.
- 1 November 2004
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 11 (6) , 453-458
Examination of the Cutaneous Absorption of Copper After the Use of Copper-Containing Ointments
Because copper-containing ointments are frequently used in anthroposophical medicine, a phase I trial to investigate the cutaneous absorption of copper was conducted. Sixty-one volunteers were randomized [group A: 0.4% copper (I) oxide, 13 men and 18 women (19–55 years); group B: 20% elementary copper, 11 men and 19 women (18–70 years)]. The ointment was applied over a 4-week period followed by a 4-week wash-out phase. Serum and urine copper concentrations were measured by atomic absorption spectrometry and hair copper concentration by inductive coupled plasma mass spectrometry. For statistical analysis, the Student t test for related random samples was used; α = 0.05 was chosen for the standard error. In group A, an increase of copper in serum and scalp hair and a decrease in urine were found in the study period. The mean serum concentration in all premenopausal women using oral contraceptives was above normal. In group B, the serum copper concentration increased significantly; in urine, it decreased, and in scalp hair, it remained stable. A higher level of serum copper was found in female volunteers using hormonal contraception. Treatment with the 2 different ointments did not cause toxic irritations on the skin, and it can therefore be deduced that the appropriate application of ointment preparations containing copper in concentrations up to 20% do not present a toxic risk.
- 1 January 2003
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 10 (1) , 40-46
Cytokine Release of a Keratinocyte Model After Incubation With Two Different Viscum album L Extracts
When injected subcutaneously, extracts from the white berry mistletoe (Viscum album L) lead to a dose-dependent local inflammatory reaction at the injection site. From in vitro investigations with V album extracts, the release of proinflammatory cytokines from peripheral blood mononuclear cells and from a human skin model (Skin 2 model; Advanced Tissue Sciences, La Jolla, CA) is known. This shows dose dependence for mistletoe lectin-I in the range of 0.02 ng/mL to 10.0 ng/mL. In this study, an investigation was conducted of which cytokines are released in the skin by the mistletoe lectin–standardized mistletoe extracts Viscum album QuFrF (VaQuFrF) and Iscador Qu Spzial (IQuS) (Institute Hiscia, Arlesheim, Switzerland) and whether dose dependency exists. The model used for this study is the multilayered skin model EpiDerm (MatTek Corporation, Ashland, MA), which consists of multilayered keratinocytes. The viability of the cell culture was measured after incubation with 0.01, 0.1, 0.2, 0.3, 0.5, and 15.0 ng/mL VaQuFrF or 0.01, 0.1, 0.2, 0.3, 0.5, 5.0, and 15.0 ng/mL IQuS. The release of interleukin (IL)-1α, IL-2, IL-6, IL-8, IL-10, IL-12p40+70, IL-12p70, tumor necrosis factor-α (TNFα), interferon (IFN)-α, IFNγ, granulocyte macrophage–colony stimulating factor, and RANTES was determined after incubation with 0.5 ng/mL of IQuS ng/mL and VaQuFrF. The dose dependency of the release of IL-1α and IL-6 after incubation with 0.5 and 15.0 ng/mL VaQuFrF or 0.5 ng/mL, 5.0 ng/mL, and 15.0 ng/mL IQuS and that of the release of IL-1α, IL-2, IL-6, IL-10, and TNFα after incubation with 0.01 ng/mL, 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, and 0.5 ng/mL VaQuFrF or IQuS were determined. A dose-dependent decrease of cellular viability and an increase of IL-1α, IL-6, and TNFα as well as the release of IL-8 could be demonstrated. These results are compatible with the hypothesis that the subcutaneous injection of VaQuFrF and IQuS leads to a release of proinflammatory cytokines at the injection site.
- 1 January 2003
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 10 (1) , 40-46
Cytokine Release of a Keratinocyte Model After Incubation With Two Different Viscum album L Extracts
When injected subcutaneously, extracts from the white berry mistletoe (Viscum album L) lead to a dose-dependent local inflammatory reaction at the injection site. From in vitro investigations with V album extracts, the release of proinflammatory cytokines from peripheral blood mononuclear cells and from a human skin model (Skin 2 model; Advanced Tissue Sciences, La Jolla, CA) is known. This shows dose dependence for mistletoe lectin-I in the range of 0.02 ng/mL to 10.0 ng/mL. In this study, an investigation was conducted of which cytokines are released in the skin by the mistletoe lectin–standardized mistletoe extracts Viscum album QuFrF (VaQuFrF) and Iscador Qu Spzial (IQuS) (Institute Hiscia, Arlesheim, Switzerland) and whether dose dependency exists. The model used for this study is the multilayered skin model EpiDerm (MatTek Corporation, Ashland, MA), which consists of multilayered keratinocytes. The viability of the cell culture was measured after incubation with 0.01, 0.1, 0.2, 0.3, 0.5, and 15.0 ng/mL VaQuFrF or 0.01, 0.1, 0.2, 0.3, 0.5, 5.0, and 15.0 ng/mL IQuS. The release of interleukin (IL)-1α, IL-2, IL-6, IL-8, IL-10, IL-12p40+70, IL-12p70, tumor necrosis factor-α (TNFα), interferon (IFN)-α, IFNγ, granulocyte macrophage–colony stimulating factor, and RANTES was determined after incubation with 0.5 ng/mL of IQuS ng/mL and VaQuFrF. The dose dependency of the release of IL-1α and IL-6 after incubation with 0.5 and 15.0 ng/mL VaQuFrF or 0.5 ng/mL, 5.0 ng/mL, and 15.0 ng/mL IQuS and that of the release of IL-1α, IL-2, IL-6, IL-10, and TNFα after incubation with 0.01 ng/mL, 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, and 0.5 ng/mL VaQuFrF or IQuS were determined. A dose-dependent decrease of cellular viability and an increase of IL-1α, IL-6, and TNFα as well as the release of IL-8 could be demonstrated. These results are compatible with the hypothesis that the subcutaneous injection of VaQuFrF and IQuS leads to a release of proinflammatory cytokines at the injection site.